Item # Length Source of Standard Year Implemented Version Implemented Year Retired Version Retired
1188 1 NAACCR/SEER 2025 25

NAACCR XML: Tumor.irssStageForEye2

Description

Bilateral retinoblastoma is abstracted as a single primary regardless of timing, but there is no effective way to measure the different extent of diseases or stages for each eye beyond text. Currently, abstractors are required to enter the information of the most advanced eye in the staging data fields, losing all measurable data on the stage the less advanced eye.

This field allows the abstractor to enter the individual stages for each eye in cases of bilateral retinoblastoma at the time of diagnosis.

Rationale

Even though staging information for only one retinoblastoma tumor can currently be captured in data form, abstractors are still required to put treatment information for bilaterally affected eyes into the treatment fields of the abstract. The ability to capture measurable staging data of the contralateral eye will provide substantiation of the treatment captured for both eyes in the abstract.

Source documents: imaging, pathology report, clinician’s statement

Codes
0Stage 0 * Tumor confined to the globe * Enucleation has not been performed * Patient treated conservatively with either focal therapies or chemotherapy
1Stage I * Enucleation with negative margins (R0) * Completely resected histologically
2Stage II * Enucleation with positive/microscopic residual tumor
3Stage III * Regional extension, involvement of  * Orbit * Preauricular extension * Cervical lymph node involvement
4Stage IV * Distant metastatic disease
7Not applicable: Only one eye is involved, and staging collected in Pediatric Primary Tumor, Pediatric Regional Nodes and Pediatric Mets * Unilateral retinoblastoma
8Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code 8 may result in an edit error.)
9Not documented in medical record International Retinoblastoma Staging System (IRSS) not assessed or unknown if assessed

Note 1: Effective years

Note 2: Bilateral retinoblastomas